Why a onetime biotech IPO hopeful shifted to a 'blank check' deal
November 08, 2021 at 18:02 PM EST
The company's lead drug targets a deadly lung-scarring disease and could start a mid-stage clinical trial in the first half of next year.
Photography by Christophe Tomatis